US$ 25.72
bpc-157 carcinogenesis study as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers Gastric pentadecapeptide body protection compound
Description
Even berberine and pectin imparted their efficacy for reducing fasting blood glucose, postprandial blood glucose, and hemoglobin A1c (HbA1c) (139)

Active ingredient: cyanocobalamin Inactive ingredients: benzalkonium chloride in purified water, citric acid, glycerin and sodium citrate

Patients buying peptides often do so without medical supervision or any assurance of quality control
BPC-157 is a research peptide not approved by Health Canada for human therapeutic use
